Citations

Showing 10 of 108152 citations.

Preferences for Updates on General Research Results: A Survey of Participants in Genomic Research from Two Institutions
Manov, Natalie Flaks, Weng, Chunhua , Connolly, John J. , Mathews, Debra , Weng, Chunhua , Caraballo, Pedro J , Holm, Ingrid A , Connolly, John J , Mathews, Debra J H , Taylor, Casey Overby , Crew, Katherine D. , Chute, Christopher G. , Ford, Daniel E , Lehmann, Harold P. , Rahm, Alanna Kulchak , Kullo, Iftikhar J. , Caraballo, Pedro J. , Holm, Ingrid A.

Mayo Clinic

Journal of Personalized Medicine | May 11, 2021 | Volume: 11 | Issue: 5 | Pages: 399

10.3390/jpm11050399 | PMID 34065005 Get It

There is a need for multimodal strategies to keep research participants informed about study results. Our aim was to characterize preferences of genomic research participants from two institutions along four dimensions of general research result updates: content, timing, mechanism, and frequency. Methods: We conducted a web-based cross-sectional survey that was administered from 25 June 2018 to 5 December 2018. Results: 397 participants completed the survey, most of whom (96%) expressed a desire to receive research updates. Preferences with high endorsement included: update content (brief descriptions of major findings, descriptions of purpose and goals, and educational material); update timing (when the research is completed, when findings are reviewed, when findings are published, and when the study status changes); update mechanism (email with updates, and email newsletter); and update frequency (every three months). Hierarchical cluster analyses based on the four update preferences identified four profiles of participants with similar preference patterns. Very few participants in the largest profile were comfortable with budgeting less money for research activities so that researchers have money to set up services to send research result updates to study participants. Conclusion: Future studies may benefit from exploring preferences for research result updates, as we have in our study. In addition, this work provides evidence of a need for funders to incentivize researchers to communicate results to participants.
Diagnosis and Treatment of Subcutaneous Panniculitis-like T-cell Lymphoma: A Systematic Literature Review
Alsomali, Dunya Yunus, Bakshi, Nasir, Kharfan‐Dabaja, Mohamed A. , Aljurf, Mahmoud , Fakih, Riad El

Mayo Clinic

Hematology/Oncology and Stem Cell Therapy | May 11, 2021 | Volume: 16 | Issue: 2 | Pages: 110-116

10.1016/j.hemonc.2021.04.001 | PMID 34015273 Get It

Objectives: The aim of this systematic review is to investigate different diagnostic methods and the available treatment options for subcutaneous panniculitis-like T-cell lymphoma (SPTCL). Methods: We searched PubMed, Web of Science, SCOPUS, EBSCO, and CINAHL Plus for published case reports of SPTCL. From each record, we extracted data of the diagnostic methods, immunohistochemical profile, clinical characteristics, and the treatment approaches provided. Data were summarized and narratively synthesized to highlight the various diagnostic methods and treatment options of SPTCL. Results: Our literature search yielded 1293 unique citations. Following screening, nine articles reporting a total of 15 cases were included in this systematic review. All patients presented with subcutaneous nodules. Three of the 15 cases were initially misdiagnosed. The atypical lymphoid cells were positive for CD2, CD3, granzyme B, and TIA-1 and negative for CD1a, EBER, and CD20 in all the reported cases. The atypical lymphoid cells were positive for CD45RO in four out of seven cases, positive for CD56 in three out of 12 cases tested, while positive for CD5 and CD8 in the majority of cases. Therapy ranged from topical agents to immunosuppressive agents all the way to multiagent chemotherapy. Conclusion: SPTCL is a rare lymphoma. Diagnosis is highly dependent on the immunohistochemical stains added to histopathologic and radiologic findings. Therapy is dependent on the pace of the disease, with encouraging results obtained with single-agent cyclosporine.
Natural Language Processing Based Machine Learning Model Using Cardiac MRI Reports to Identify Hypertrophic Cardiomyopathy Patients
Sundaram, Divaakar Siva Baala, Damani, Devanshi N. , Farahani, Nasibeh Zanjirani , Enayati, Moein , Arruda‐Olson, Adelaide M. , Arunachalam, Shivaram P. , Arunachalam, S P , Pasupathy, Kalyan S.

Mayo Clinic

2021 Design of Medical Devices Conference | May 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/dmd2021-1076 | PMID 35463194 Get It

Abstract Hypertrophic Cardiomyopathy (HCM) is the most common genetic heart disease in the US and is known to cause sudden death (SCD) in young adults. While significant advancements have been made in HCM diagnosis and management, there is a need to identify HCM cases from electronic health record (EHR) data to develop automated tools based on natural language processing guided machine learning (ML) models for accurate HCM case identification to improve management and reduce adverse outcomes of HCM patients. Cardiac Magnetic Resonance (CMR) Imaging, plays a significant role in HCM diagnosis and risk stratification. CMR reports, generated by clinician annotation, offer rich data in the form of cardiac measurements as well as narratives describing interpretation and phenotypic description. The purpose of this study is to develop an NLP-based interpretable model utilizing impressions extracted from CMR reports to automatically identify HCM patients. CMR reports of patients with suspected HCM diagnosis between the years 1995 to 2019 were used in this study. Patients were classified into three categories of yes HCM, no HCM and, possible HCM. A random forest (RF) model was developed to predict the performance of both CMR measurements and impression features to identify HCM patients. The RF model yielded an accuracy of 86% (608 features) and 85% (30 features). These results offer promise for accurate identification of HCM patients using CMR reports from EHR for efficient clinical management transforming health care delivery for these patients.
Application of Machine Learning for Detection of Hypertrophic Cardiomyopathy Patients from Echocardiogram Measurements
Farahani, Nasibeh Zanjirani , Enayati, Moein , Sundaram, Divaakar Siva Baala, Damani, Devanshi N. , Kaggal, Vinod C. , Zacher, April L., Arruda‐Olson, Adelaide M. , Arunachalam, S P , Geske, Jeffrey B. , Kane, Garvan C. , Arunachalam, Shivaram P. , Pasupathy, Kalyan S.

Mayo Clinic

2021 Design of Medical Devices Conference | May 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/dmd2021-1078 Get It

Abstract Hypertrophic cardiomyopathy (HCM) is a heritable, phenotypically diverse, and often asymptomatic heart muscle disease which is a major cause of sudden cardiac death (SCD) in young adults. The gold-standard for the diagnosis of HCM is echocardiography (echo), which is an ultrasound-based cardiac imaging modality. Across all sites of the Mayo Clinic enterprise, echo images and measurement data are reviewed, interpreted, and reported via the Echo Information Management System (EIMS). The objective of this paper is to develop a machine learning model for the identification of HCM from cardiac measurements obtained by the echo. We developed a novel machine learning model on patient demographic information and echo measurements that were retrieved from the EIMS digital data registry and selected by cardiologists. Random forest (RF) was utilized to investigate the predictive performance of these features on the identification of HCM patients. The HCM cohort consists of 3,548 patients with at least one HCM diagnostic billing code (ICD-9 or ICD-10), from 2014 to 2019. The class labels “HCM yes” and “HCM no” were assigned by manual review of medical records as well as the outcomes of the gold standard imaging tests for HCM diagnosis. The developed model performed well in finding HCM patients with an accuracy of 95%, recall of 99%, and precision of 97%. The F1 score was 98 %, while 4% of patients were misclassified. This model will be translated into clinical practice for a clinical decision support system in EIMS to assist providers in the accurate diagnosis of HCM from echo data automatically while ensuring high-quality echo interpretation.
An Agitated Patient With COVID-19 Infection and Early-onset Alzheimer Disease
Sykora, Daniel , Stonnington, Cynthia M. , Jain, Neeta

Mayo Clinic

Alzheimer Disease & Associated Disorders | May 11, 2021 | Volume: 36 | Issue: 1 | Pages: 83-84

10.1097/wad.0000000000000456 | PMID 33973880 Get It

Encephalopathy, delirium, and agitation are documented symptoms of coronavirus disease (COVID-19) infection, but research into the management of agitation in the setting of COVID-19 and pre-existing neuropsychiatric disease is ongoing. We present a 55-year-old male patient with early-onset Alzheimer disease and deteriorating mental and functional status who presented to our institution with agitation and persistent COVID-19 positivity on polymerase chain reaction testing. His agitation was improved through pharmacologic optimization including the avoidance of benzodiazepines and initiation of clonidine and prazosin, which temporally coincided with the resolution of his nearly 2-month long COVID-19 positivity.
Midterm Results of Primary Exeter Cemented Stem in a Select Patient Population
Gausden, Elizabeth B. , Abdel, Matthew P. , Mabry, Tad M. , Berry, Daniel J. , Trousdale, Robert T. , Sierra, Rafael J. , Abdel, Matthew P , Sierra, Rafael J , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | May 11, 2021 | Volume: 103 | Issue: 19 | Pages: 1826-1833

10.2106/jbjs.20.01829 | PMID 33974592 Get It

Background: Most North American surgeons predominantly use uncemented stems in primary total hip arthroplasties (THAs) and reserve cemented stems for selected older patients and those with poor bone quality. However, data on this “selective use” strategy for cemented stems in the population at risk for periprosthetic fracture and implant loosening are limited. The purpose of this study was to describe implant survivorship, complications, and radiographic results of a specific collarless, polished, tapered cemented stem (Exeter; Stryker) used selectively in a predominantly elderly population undergoing primary THA. Methods: We identified 386 patients who underwent a total of 423 primary THAs with selectively utilized Exeter stems for the treatment of osteoarthritis between 2006 and 2017. In the same time period, 11,010 primary THAs were performed with uncemented stems and 961 with non-Exeter cemented stems. The mean patient age was 77 years, 71% were female, and the mean body mass index was 29 kg/m 2 . Competing risk analysis accounting for death was utilized to determine cumulative incidences of revision and reoperation. The mean follow-up was 5 years (range, 2 to 12 years). Results: The 10-year cumulative incidence of any femoral component revision in this patient cohort was 4%, with 10 stems revised at the time of the latest follow-up. There were no intraoperative femoral fractures. The indications for revision were postoperative periprosthetic femoral fracture (n = 6), dislocation (n = 3), and infection (n = 1). There were no revisions for femoral loosening. The 10-year cumulative incidence of reoperation was 10%. The 10-year cumulative incidence of Vancouver B periprosthetic femoral fracture was 2%. Radiographically, there were no cases of aseptic loosening or osteolysis. There was a significant improvement in median Harris hip score, from 53 preoperatively to 92 at a mean follow-up of 5 years (p < 0.001). Conclusions: The strategy of selectively utilizing a collarless, polished, tapered cemented stem produced a low (4%) cumulative incidence of stem revision at 10 years postoperatively and resulted in no cases of aseptic loosening. The use of the Exeter stem did not eliminate postoperative femoral fractures in this predominantly elderly, female patient population. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Alteration of fibrin hydrogel gelation and degradation kinetics through addition of azo dyes
Gandhi, Jarel K. , Heinrich, Lauren , Kim, Minkyu , Marmorstein, Alan D. , Marmorstein, Alan D , Heinrich, Lauren, Knoff, David S.

Mayo Clinic

Journal of Biomedical Materials Research Part A | May 11, 2021 | Volume: 109 | Issue: 11 | Pages: 2357-2368

10.1002/jbm.a.37218 | PMID 33973708 Get It

AbstractFibrin is a degradable biopolymer with an excellent clinical safety profile. Use of higher mechanical strength fibrin hydrogels is limited by the rapid rate of fibrin polymerization. We recently demonstrated the use of higher mechanical strength (fibrinogen concentrations >30 mg/ml) fibrin scaffolds for surgical implantation of cells. The rapid polymerization of fibrin at fibrinogen concentrations impaired our ability to scale production of these fibrin scaffolds. We serendipitously discovered that the azo dye Trypan blue (TB) slowed fibrin gelation kinetics allowing for more uniform mixing of fibrinogen and thrombin at high concentrations. A screen of closely related compounds identified similar activity for Evans blue (EB), an isomer of TB. Both TB and EB exhibited a concentration dependent increase in clot time, though EB had a larger effect. While gelation time was increased by TB or EB, overall polymerization time was unaffected. Scanning electron microscopy showed similar surface topography, but transmission electron microscopy showed a higher cross‐linking density for gels formed with TB or EB versus controls. Based on these data we conclude that addition of TB or EB during thrombin mediated fibrin polymerization slows the initial gelation time permitting generation of larger more uniform fibrin hydrogels with high‐mechanical strength.
Outcomes After Proton Therapy Reirradiation for Malignant Glioma: Prospective Analysis of Over 100 Patients from the Proton Collaborative Group
Press, Robert H. , Choi, J. Isabelle , Chhabra, Arpit M. , Halasz, Lia M. , Vargas, Carlos , Wang, Chiachien J., Chang, John, Gondi, Vinai , Mishra, Mark V. , Mishra, Mark V , Hasan, Shaakir , Tsai, Henry K. , Simone, Charles B.

Mayo Clinic

No container title available | May 11, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-499865/v1 Get It

Abstract Purpose: The optimal salvage treatment for malignant glioma after prior radiotherapy (RT) is not well established. Proton therapy (PT) is an attractive treatment modality for reirradiation (ReRT) of recurrent disease; however, data are limited.Methods: The prospective, multi-institutional Proton Collaborative Group (PCG) registry was queried for patients with malignant glioma who previously received RT and underwent PT-ReRT between 7/2011-10/2018. Overall survival (OS) and progression-free survival (PFS) were assessed using the Kaplan-Meier method and Cox proportional hazards regression analysis. Results: 109 consecutive patients were identified. Median follow-up was 11.2 months and median time interval (TI) from prior RT (median 59.3 Gy) to PT-ReRT (median 49.6 Gy) was 45.7 months. Primary histology was glioblastoma (n=62), oligodendroglioma (n=26), and astrocytoma (n=20). Median PFS and OS was 6.1 and 11.1 months, respectively. On UVA, improved PFS was associated with oligodendroglioma (HR 0.39) and astrocytoma (HR 0.55) histologies, WHO Grade III (HR 0.36), TI (HR 0.989), surgical resection (HR 0.39), and PT-ReRT dose ≥50 Gy (HR 0.59) (all p<0.03), while improved OS was associated with oligodendroglioma histology (HR 0.35), WHO grade III (HR 0.33), ECOG 0 (HR 0.47), TI (HR 0.985), and PT-ReRT dose ≥50 Gy (HR 0.58) (all p<0.04). Late Grade 3 toxicities occurred in 5.6% of patients with no attributable acute or late Grade 4-5 events.Conclusion: In the largest series of glioma PT-ReRT reported to date, retreatment appears well tolerated with acceptable outcomes and favorable toxicities compared to photon historical controls. Dose escalation achievable with PT may improve outcomes for well-selected patients.
A Survey of Urology Residency Program Directors Assessing Criteria to Interview Applicants during the COVID-19 Pandemic
Ahmed, Mohamed E. , Joshi, Vidhu B. , Alamiri, Jamal, Granberg, Candace F. , Thompson, R. Houston, Viers, Boyd R. , Thompson, R. Houston

Mayo Clinic

Urology Practice | May 11, 2021 | Volume: 8 | Issue: 4 | Pages: 472-479

10.1097/upj.0000000000000233 | PMID 37145462 Get It

Editorial Commentary
Wymer, Kevin , Koo, Kevin

Mayo Clinic

Urology Practice | May 11, 2021 | Volume: 8 | Issue: 4 | Pages: 502-502

10.1097/upj.0000000000000230.01 | PMID 37145480 Get It